The venture capital market remains weak, but M&A activity is still strong and R&D spending is on an upward trend, conclude two state-of-the-industry reports released by EY (formerly Ernst & Young) and EvaluateMedTech and at the annual AdvaMed industry conference.
HeartWare was up about 5% in early trading on the news that activist investor Engaged Capital is opposing its acquisition of mitral valve player Valtech Cardio--and is seeking a renewed focus on LVAD with a possible sale of the company. If the deal is not terminated, Engaged Capital said it will continue to oppose it and seek board representation.
AtriCure said it will buy startup nContact as well as narrow its 2015 revenue guidance to the high end of a previously disclosed range. The public cardiac player, which is focused on atrial fibrillation and left atrial appendage management, will purchase the cardiac ablation company for $8 million in upfront cash, 3.7 million in AtriCure shares and up to $50 million in additional regulatory milestones.
Veeva Systems bought its nearest competitor in life science content management systems, Zinc Ahead, in a $130 million purchase that will combine the top two companies in the specialized field.
Getting patients to stick to their meds is a big problem in treating pulmonary diseases. So to boost adherence for its respiratory portfolio, Teva Pharmaceuticals is turning to technology.
Last month, names like Sanofi, Pfizer, Abbott and Takeda were flying around as potential suitors for Mexico-based Representaciones e Investigaciones Medicas, aka Rimsa. But it's Teva that's emerged victorious in the field.
C.R. Bard will acquire the outstanding shares of a Japan-based joint venture that it has been invested in for about 40 years with Kobayashi Pharmaceutical, Medicon. The New Jersey-based med tech will acquire Kobayashi's 50% ownership stake for a total of 11.2 billion yen ($93.2 million) doled out over the next 10 years. The purchase is expected to give Bard more of a foothold in the Japanese market.
Now-Ireland's Medtronic said in a filing with the SEC that it is paying $500 million in U.S. income taxes on $9.8 billion in cash and investments that it is moving to the country from overseas subsidiaries. The move sets the stage for more M&A activity. After all, the U.S. is the capital of med tech innovation (if not manufacturing).
If Horizon wants to make any headway in its hostile pursuit of Depomed, it's going to have to call a pair of shareholder meetings. First, though, its target's shareholders have to provide consent for those meetings--something proxy advisory firm ISS recommends they do.
Smiths Medical has faced its fair share of buyout rumors, with lagging revenues for its infusion pump business leaving some wondering when the company would close up shop. But the Minnesota devicemaker is undergoing a transformation under the stewardship of new CEO Jeff McCaulley, shrugging off talk of M&A as it revives its flagging fortunes.